It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Our Self Pay Program

Because cost should not be an obstacle on your treatment journey

We know that unexpected costs and delays to your treatment journey can be stressful. For patients without insurance or who wish to skip the reimbursement process, cost-saving options are available to help you save thousands per month.1

Eligible* patients may save an average of over $5,000 per month,
versus wholesale acquisition cost.1

The Omnitrope® Self Pay Program is the most comprehensive among daily somatropins because it includes two formulation options to meet your needs. Take a look at our full price breakdown below:

Omnitrope Vial and Syringe
Omnitrope Pen 5/10

To get started, speak to your doctor or contact OmniSource® today

If you’re interested in our Self Pay Program, speak to your doctor or contact us today at 877.456.6794.

Reference

1. Data on File. Potential savings based upon 1) average monthly liquid milligram usage by Omnitrope Self Pay patients during 2020, and 2) Omnitrope liquid wholesale acquisition cost as of January 2021. This is not a guarantee of any particular savings or cost reduction, and individual results may vary.


Savings

Get savings support with Co-Pay

Eligible patients may pay $0 for their co-pay.
 

Your Journey

Your OmniSource journey 

Here’s a look at what to expect, step by step, along the growth journey.

Get started with OmniSource today

Omnisource


Personalized support, each step of the way. Click here to enroll.

*Omnitrope Self Pay Program:
Prescriptions must be for an approved indication. This program is not health insurance. Patients are not eligible if this prescription is paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, TriCare, private indemnity, or HMO insurance plans that reimburse you for the entire cost of Omnitrope, or where prohibited by law. Patients with a state or federally funded program that does not cover any of the cost for their Omnitrope prescription are eligible to participate. Patients may continue to participate as long as they meet the eligibility criteria. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.
Omnitrope Co-Pay Savings Program Eligibility:
The Omnitrope Co-Pay Savings Program provides up to $5,000 in annual co-pay support for Omnitrope prescriptions. With the Omnitrope Co-Pay Savings Program, eligible patients may pay $0 for their co-pay. Eligible patients who are commercially insured may receive co-pay support in the amount of up to $5,000 annually, and patients who are uninsured may receive co-pay support in the amount of up to $417 monthly, with an annual cap of $5,000. Prescription must be for an approved indication. This program is not health insurance. Patients are not eligible if prescriptions are paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TRICARE, or private indemnity, or HMO insurance plans that reimburse you for the entire cost of your prescription drugs, or where prohibited by law. Patients can participate for a maximum of 12 months. Eligible patients must have a first use of the program by December 31 of the current year. Omnitrope Co-Pay Savings Program may not be combined with any other rebate, coupon, or offer. Omnitrope Co-Pay Savings Program has no cash value. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.

INDICATIONS

Omnitrope is a prescription medicine that contains human growth hormone and is used to treat:

  • Children with growth failure due to growth hormone deficiency (GHD), Prader-Willi Syndrome, Small for Gestational Age, Turner Syndrome, and Idiopathic Short Stature
  • Adults with either adult onset or childhood onset GHD

IMPORTANT SAFETY INFORMATION

Who should not take Omnitrope®?

Omnitrope should not be used by children or adults that have:

  • a critical illness caused by certain types of heart or stomach surgery, accidental trauma, or a sudden and severe breathing problem (respiratory failure)
  • Prader-Willi syndrome who are severely overweight or have a history of breathing problems including sleep apnea
  • cancer or other tumors
  • allergies to growth hormone or any of the ingredients in the medicine
  • certain types of eye problems caused by diabetes
  • closed bone growth plates

What should patients tell their healthcare provider before taking Omnitrope?

Patients should tell their healthcare provider about all of their medical conditions, including if they:

  • have had heart or stomach surgery, trauma, or serious breathing problems
  • have or have had cancer or any tumor
  • have diabetes
  • take any prescription and non-prescription medicines, steroids, vitamins, or herbal supplements
  • are pregnant or breastfeeding, or plan to become pregnant or breastfeed

What are the most common side effects of Omnitrope?

  • local reactions at the injection site (such as pain, numbness, redness and swelling)
  • headaches
  • swelling associated with fluid retention
  • pain in joints and muscle pain
  • carpal tunnel syndrome
  • tingling and numbness
  • high blood sugar (hyperglycemia/diabetes) and sugar in your urine (glucosuria)
  • unusual skin sensations
  • low levels of thyroid hormone (hypothyroidism)

Other possible side effects of Omnitrope are:

  • return of tumor or cancerous growths
  • headaches, changes in vision, nausea or vomiting (these may be symptoms of raised pressure in the brain which requires immediate medical attention)
  • hip and knee pain or a limp in children, that can be a sign of slipped capital femoral epiphysis
  • worsening of pre-existing curvature of the spine in children (scoliosis)
  • increased ear infections and ear disorders in children with Turner syndrome; check for cardiovascular disorders (hypertension, stroke)
  • intense pain and tenderness in the abdomen as consequence of an inflammation of the pancreas (pancreatitis)
  • gasping syndrome (decreased rate of breathing) in children from high levels of benzyl alcohol (an inactive ingredient)
  • Increased mortality in patients with Prader Willi and acute illness

Please see full Prescribing Information for Omnitrope

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch